Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

aHUS caused by complement dysregulation: new therapies on the horizon.

Pediatric nephrology (Berlin, Germany) - 1 Jan 2011

Waters Aoife M, Licht Christoph

Abstract excerpt

Atypical hemolytic uremic syndrome (aHUS) is a heterogeneous disease that is caused by defective complement regulation in over 50% of cases. Mutations have been identified in genes encoding both complement regulators [complement factor H (CFH), complement factor I (CFI), complement factor H-related proteins (CFHR), and membrane cofactor protein (MCP)], as well as complement activators [complement factor B (CFB)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement System Proteins

Share to Gene Expression Regulation

Share to Hemolytic-Uremic Syndrome

Share to Immunologic Factors

Share to Kidney Transplantation

Source

Open in PubMed Open full text

Identifiers

PMID: 20556434
DOI: 10.1007/s00467-010-1556-4
PMCID: PMC2991208

Genes

CFH
CFI
CFB
THBD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

aHUS caused by complement dysregulation: new therapies on the horizon.PMID 20556434Read ↗

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)Semantic proximity Read ↗

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSSemantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

Atypical hemolytic uremic syndrome: update on the complement system and what is new.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

Consensus regarding diagnosis and management of atypical hemolytic uremic syndromeSemantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Complement-mediated HUS revisited: evolving insights into pathophysiology, diagnosis, and treatment.Semantic proximity Read ↗

How I diagnose and treat atypical hemolytic uremic syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.